We are live on ! Find out more
PVMCV

Polaris Venture Management Co V Portfolio holdings

AUM $14.1M
1-Year Est. Return 121.41%
This Fund
S&P 500
This Quarter Est. Return
+12.04%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$19.7M
Cap. Flow
+$36.3M
Cap. Flow %
31.19%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$41.5M

Top Sells

Rank Stock Value
1
RNAC icon
Cartesian Therapeutics
RNAC
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 93.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
1
KALA BIO
KALA
$13.6M
$43.2M 37.13%
+757
New +$41.5M
RNAC icon
2
Cartesian Therapeutics
RNAC
$227M
$29.7M 25.53%
54,251
-9,887
-15% -$5.26M
FATE icon
3
Fate Therapeutics
FATE
$293M
$9.79M 8.42%
2,473,186
– –
ATYR
4
aTyr Pharma
ATYR
$47.1M
$9.23M 7.94%
130,571
– –
TTOO
5
DELISTED
T2 Biosystems, Inc
TTOO
$7.88M 6.77%
375
– –
PULM icon
6
Pulmatrix
PULM
$6.21M
$7.4M 6.36%
18,040
– –
TRVN
7
DELISTED
Trevena, Inc.
TRVN
$5.24M 4.5%
3,286
– –
GNCA
8
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.87M 2.47%
246,076
– –
DARE icon
9
Dare Bioscience
DARE
$18.6M
$1.03M 0.88%
27,396
– –

Similar funds

IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
AG
Ashmore Group London, United Kingdom $16.3M AUM 57.83% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
EIP
Edgbaston Investment Partners $20.3M AUM 35.98% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
OEP
Ocean Endowment Partners Chicago, Illinois $20.6M AUM 27.63% 1-Year Est. Return

Polaris Venture Management Co V's Q3 2017 Portfolio in Review

As of Q3 2017, Polaris Venture Management Co V held 9 positions worth $116M, up 20% from $96.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Polaris Venture Management Co V deployed $36.3M of net new capital in Q3 2017, opening 1 new position. Its largest new stake was KALA BIO: 757 shares worth $43.2M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Cartesian Therapeutics, an estimated $5.26M trimmed.

  • Polaris Venture Management Co V's largest Q3 2017 buy was KALA BIO: 757 shares worth $43.2M.
  • Polaris Venture Management Co V's biggest Q3 2017 reduction was Cartesian Therapeutics, cutting an estimated $5.26M.
  • Polaris Venture Management Co V's ten largest holdings make up 100% of its $116M portfolio in Q3 2017.
  • Polaris Venture Management Co V opened 1 new position and closed 0 in Q3 2017.
  • Polaris Venture Management Co V's portfolio value rose 20% quarter-over-quarter to $116M.

Based on Polaris Venture Management Co V's 13F filing for Q3 2017, filed 14 Nov 2017.